Patents by Inventor Maria Argese
Maria Argese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11739099Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: GrantFiled: January 26, 2021Date of Patent: August 29, 2023Assignee: CURIA IP HOLDINGS, LLCInventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Publication number: 20230242476Abstract: The present invention relates to a process for the purification of (R)-2-amino-3-phenylpropyl carbamate in perspective of the subsequent conversion in the corresponding HCl salt (SOLRIAMFETOL). The invention further relates to the process for preparing a batch of purified solriamfetol, as well as to the purified (R)-2-amino-3-phenylpropyl carbamate or its hydrochloride salt.Type: ApplicationFiled: June 9, 2021Publication date: August 3, 2023Applicant: FLAMMA SPAInventors: Francesco CHIESA, Leila VAHDATI, Mario SCOTTI, Daniela COMI, Paolo CREMONESI, Maria ARGESE, Massimo VERZINI, Wei HE
-
Publication number: 20230234966Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: ApplicationFiled: March 29, 2023Publication date: July 27, 2023Inventors: Paride GRISENTI, Maria ARGESE, Daniele PENGO, Maria Donata GRILLI, Emanuela FUMAGALLI, Giuseppe MOTTA
-
Publication number: 20220048926Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: ApplicationFiled: October 29, 2021Publication date: February 17, 2022Inventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Publication number: 20220041622Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: ApplicationFiled: January 26, 2021Publication date: February 10, 2022Inventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Publication number: 20210147444Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: ApplicationFiled: January 26, 2021Publication date: May 20, 2021Inventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Patent number: 10961257Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: GrantFiled: September 12, 2019Date of Patent: March 30, 2021Assignee: AMRI ITALY S.R.L.Inventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Patent number: 10745415Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: GrantFiled: September 11, 2019Date of Patent: August 18, 2020Assignee: AMRI ITALY S.R.L.Inventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Patent number: 10556915Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: GrantFiled: March 24, 2015Date of Patent: February 11, 2020Assignee: EUTICALS SPAInventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Publication number: 20200002356Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: ApplicationFiled: September 11, 2019Publication date: January 2, 2020Inventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Publication number: 20200002357Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: ApplicationFiled: September 12, 2019Publication date: January 2, 2020Inventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Patent number: 10457635Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.Type: GrantFiled: December 22, 2017Date of Patent: October 29, 2019Assignee: BRACCO IMAGING S.p.A.Inventors: Pier Lucio Anelli, Maria Argese, Valeria Boi, Livio Cavalieri, Laura Galimberti, Sonia Gazzetto, Luciano Lattuada, Federico Maisano, Giovanni Rivolta, Fulvia Vella
-
Patent number: 10144756Abstract: A process for the preparation of the amorphous form of Regadenoson of formula is disclosed together with new crystalline polymorphic forms E, F and G and methods for their preparation. Regadenoson amorphous form can be prepared in mild reaction conditions with high chemical purity (>99.6%) and high stability to the heating. A particularly thermodynamically stable anhydrous crystalline form of Regadenoson (form G) is also disclosed, provided with high stability not when exposed to 90% RH at 25° C. for 96 hour, but also to the heating up to 200° C.Type: GrantFiled: October 7, 2015Date of Patent: December 4, 2018Inventors: Paride Grisenti, Elahi Shahrzad Reza, Giuseppe Guazzi, Maria Argese
-
Publication number: 20180118669Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.Type: ApplicationFiled: December 22, 2017Publication date: May 3, 2018Applicant: BRACCO IMAGING S.p.A.Inventors: Pier Lucio ANELLI, Maria ARGESE, Valeria BOI, Livio CAVALIERI, Laura GALIMBERTI, Sonia GAZZETTO, Luciano LATTUADA, Federico MAISANO, Giovanni RIVOLTA, Fulvia VELLA
-
Patent number: 9890116Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chloro-sulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.Type: GrantFiled: April 5, 2012Date of Patent: February 13, 2018Assignee: BRACCO IMAGING S.p.A.Inventors: Pier Lucio Anelli, Maria Argese, Luciano Lattuada, Sonia Gazzetto, Laura Galimberti, Valeria Boi, Livio Cavalieri, Fulvia Vella
-
Patent number: 9765082Abstract: A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endothermic event at about 191-193° C. determined by DSC. A process for the preparation of the cocrystal is also disclosed. Preferably, the cocrystal has a particle size distribution of D90<10 ?m. The cocrystal is also disclosed for use as medicament, in particular for the treatment of a respiratory complaint, such as chronic obstructive pulmonary disease (COPD), bronchitis, emphysema and asthma. A pharmaceutical composition comprising the cocrystal as active ingredient is also disclosed, in particular for administration by inhalation. In the latter case, said cocrystal has a mean particle size of 0.5 to 10 ?m, preferably 1 to 6 ?m, more preferably 1.5 to 5 ?m.Type: GrantFiled: August 23, 2016Date of Patent: September 19, 2017Assignee: EUTICALS SPAInventors: Paride Grisenti, Maria Argese, Roberto Scrocchi, Alessandro Livieri, Giuseppe Guazzi
-
Publication number: 20170044176Abstract: A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endothermic event at about 191-193° C. determined by DSC. A process for the preparation of the cocrystal is also disclosed. Preferably, the cocrystal has a particle size distribution of D90<10 ?m. The cocrystal is also disclosed for use as medicament, in particular for the treatment of a respiratory complaint, such as chronic obstructive pulmonary disease (COPD), bronchitis, emphysema and asthma. A pharmaceutical composition comprising the cocrystal as active ingredient is also disclosed, in particular for administration by inhalation. In the latter case, said cocrystal has a mean particle size of 0.5 to 10 ?m, preferably 1 to 6 ?m, more preferably 1.5 to 5 ?m.Type: ApplicationFiled: August 23, 2016Publication date: February 16, 2017Inventors: Paride Grisenti, Maria Argese, Roberto Scrocchi, Alessandro Livieri, Giuseppe Guazzi
-
Publication number: 20170015682Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.Type: ApplicationFiled: March 24, 2015Publication date: January 19, 2017Inventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
-
Publication number: 20160024137Abstract: A process for the preparation of the amorphous form of Regadenoson of formula is disclosed together with new crystalline polymorphic forms E, F and G and methods for their preparation. Regadenoson amorphous form can be prepared in mild reaction conditions with high chemical purity (>99.6%) and high stability to the heating. A particularly thermodynamically stable anhydrous crystalline form of Regadenoson (form G) is also disclosed, provided with high stability not when exposed to 90% RH at 25° C. for 96 hour, but also to the heating up to 200° C.Type: ApplicationFiled: October 7, 2015Publication date: January 28, 2016Inventors: Paride Grisenti, Elahi Shahrzad Reza, Giuseppe Guazzi, Maria Argese
-
Publication number: 20140221477Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.Type: ApplicationFiled: April 10, 2014Publication date: August 7, 2014Applicant: BRACCO IMAGING S.P.A.Inventors: Pier Lucio ANELLI, Maria ARGESE, Valeria BOI, Livio CAVALIERI, Laura GALIMBERTI, Sonia GAZZETTO, Luciano LATTUADA, Fulvia VELLA